The mixed Q2 (flat reported EPS at CER, BioPharma decline) and Wainua failure temper the otherwise solid H1 growth. Monitor Farxiga generic erosion trajectory and China VBP impact on Lynparza/roxadustat. The Dizal and Sino Biopharma deals add pipeline depth but increase near-term cash outflows. Guidance reaffirmation provides a floor, but the stock may trade range-bound until pipeline catalysts (elecoglipron, sonesitatug vedotin readouts) materialize.
Drugs in focus
AZN drug pipeline →Tagrisso
● Neutral Named in this 6-K- Impact
- Phase
- Approved
- Time to market
- Approved and marketed since 2015 (first FDA approval Nov 2015)
- Next catalyst
- None dated
What to watchTagrisso is AZN's largest drug at $7.3B in 2025 revenue, but it is already fully de-risked and commercialized. The near-term investor debate centers on how quickly J&J's Rybrevant/lazertinib combo erodes first-line share and how far label expansion (LAURA Stage III) boosts volume, gradual commercial trends, not binary events. Watch quarterly sales growth rates and the LAURA OS readout for the next meaningful update.
- ● trastuzumab deruxtecan 4/10 Approved Named in filing
- ▼ Wainua 4/10 Approved Named in filing
- ● Amlypave 3/10 Approved (Japan); Phase 3 completed globally Named in filing
- ▲ Datroway 3/10 Approved Named in filing
- ● sunvozertinib 3/10 Approved (China); Phase 3 first-line data filed for approval Named in filing
- 5 more · All AZN drugs, catalysts & trials →
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 27 $169.64entry
- T+1 · 4mo ago +1.67%α +1.43% · $172.48
- T+5 · 4mo ago 0.00%α −1.07% · $169.64
- T+20 · 3mo ago −1.75%α −5.05% · $166.68
- T+60 · 28d ago −0.48%α −4.54% · $168.82
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
AstraZeneca reported H1 2026 Total Revenue of $30.7B (+6% CER) and Core EPS of $5.21 (+11% CER), with strong double-digit growth in Oncology and Rare Disease offset by BioPharmaceuticals headwinds from Farxiga US loss of exclusivity and China VBP. Q2 2026 Reported EPS was essentially flat (+2% actual, -2% CER) as R&D and SG&A spending increased. The company reconfirmed FY 2026 guidance (mid-to-high single-digit revenue growth, low double-digit Core EPS growth) and announced two license deals (Dizal $600M upfront, Sino Biopharma $200M upfront), but the Wainua CARDIO-TTRansform Phase III failure in ATTR-CM is a notable pipeline setback.
Key Facts
- Total Revenue H1 2026: $30,672M (+9% actual, +6% CER); Q2: $15,384M (+6% actual, +5% CER)
- Reported EPS H1: $3.60 (+4% actual, +3% CER); Q2: $1.61 (+2% actual, -2% CER)
- Core EPS H1: $5.21 (+12% actual, +11% CER); Q2: $2.63 (+21% actual, +18% CER)
- Oncology Product Revenue H1: $14,123M (+18% actual, +15% CER); Rare Disease: $4,911M (+13% actual, +11% CER)
- BioPharmaceuticals Total Revenue H1: $11,151M (-1% actual, -5% CER) driven by Farxiga decline (-5% actual, -11% CER) and Brilinta decline (-64% actual, -66% CER)
- Farxiga US LOE: multiple generics launched in Q2 2026; US Farxiga revenue -17% actual in H1
- Wainua Phase III CARDIO-TTRansform in ATTR-CM did not meet primary efficacy endpoint
- Impairment charges of $345M recorded against intangible assets in Q2 2026
- License agreement with Dizal for Zegfrovy: $600M upfront, up to $900M milestones
- License agreement with Sino Biopharmaceutical for TQC3721: $200M upfront, up to $1.9B milestones
- Interim dividend increased 3 cents to $1.06 per share; FY 2026 annual dividend intended to increase to $3.30 per share
- Guidance reaffirmed: FY 2026 Total Revenue mid-to-high single-digit % increase, Core EPS low double-digit % increase at CER
Financial Impact
H1 2026 Total Revenue $30.7B (+6% CER), Core Operating Profit $10.5B (+11% CER), Core EPS $5.21 (+11% CER). BioPharma revenue decline of -5% CER (~$600M headwind) partially offset by Oncology +15% CER and Rare Disease +11% CER. Net debt increased $3.5B to $26.9B. Two license deals add ~$800M in upfront payments.
Risk Factors
- Farxiga US LOE accelerating (multiple generics launched Q2 2026)
- Wainua ATTR-CM failure removes a key pipeline opportunity
- China VBP and generic competition pressuring Lynparza, roxadustat, Brilinta
- R&D spend increasing (+13% CER Q2) may pressure margins
- Net debt rising to $26.9B with two new license deals adding $800M upfront
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001104659-26-086846 |
| Document: 0001104659-26-086846-index-headers.html | 0001104659-26-086846 |
| Document: 0001104659-26-086846-index.html | 0001104659-26-086846 |
| Document: 0001104659-26-086846.txt | 0001104659-26-086846 |
Track record
77 reports on AZN
19 of 38 bullish or bearish reports moved the stock their way by T+5. Best: +20.72% at T+60 after the Aug 17, 2026 report. 29 of 38 went positive at some point.
Filters
- Nov 16, 2026today 6-K Bullish 6/10 Entry price pending
- Nov 16, 2026today 6-K Bullish 6/10 Entry $185.55 Now $184.02 −0.82% settles Nov 23
- Nov 16, 2026today 6-K Bullish 6/10 Entry $185.31 Now $184.02 −0.70% settles Nov 23
- Nov 16, 2026today 6-K Bullish 5/10 Entry $185.09 Now $184.02 −0.58% settles Nov 23
- Nov 4, 202612d ago Institutional Cluster Mixed 3/10 Entry $186.85 to $184.38 Now $184.02 −1.51% ▼ −1.32% −4.61% vs SPY
- Nov 2, 202614d ago 6-K Neutral 1/10 Entry $186.58 to $189.39 Now $184.02 −1.37% ▲ +1.51% +1.43% vs SPY
- Nov 2, 202614d ago 6-K Neutral 1/10 Entry $186.58 to $189.39 Now $184.02 −1.37% ▲ +1.51% +1.43% vs SPY
- Oct 30, 202617d ago 6-K Neutral 5/10 Entry $186.65 to $186.43 Now $184.02 −1.41% ▼ −0.12% +2.59% vs SPY
- Oct 27, 202620d ago 6-K Bullish 5/10 Entry $170.08 to $183.88 Now $184.02 +8.20% ▲ +8.11% +10.10% vs SPY
- Oct 22, 202625d ago 6-K Bullish 6/10 Entry $172.57 to $173.46 Now $184.02 +6.63% ▲ +0.51% −0.19% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers